STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
Open Access
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 14 (4) , 101027
Abstract
No abstract availableKeywords
Funding Information
- Biocenter Finland
- Helsinki Institute of Life Science, Helsingin Yliopisto
- VINNOVA
- Research Council of Finland (278741, 333583)
- Sigrid Juséliuksen Säätiö (9V068)
- Syöpäjärjestöt
This publication has 33 references indexed in Scilit:
- Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion GeneAmerican Journal of Surgical Pathology, 2016
- Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK‐related tumour spectrumHistopathology, 2015
- Patient-derived models of acquired resistance can identify effective drug combinations for cancerScience, 2014
- Immunohistochemistry in Undifferentiated Neoplasm/Tumor of Uncertain OriginArchives of Pathology & Laboratory Medicine, 2014
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesScientific Reports, 2014
- Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancerProceedings of the National Academy of Sciences, 2014
- Identification of a Recurrent STRN/ALK Fusion in Thyroid CarcinomasPLOS ONE, 2014
- Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaCancer Discovery, 2013
- Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast CancerThe American Journal of Pathology, 2009